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article under the CC BY-NC-ND licenseAbstract Few pharmacotherapies are currently available to treat castration resistant pros-
tate cancer (CRPC), with low impact on patient survival. Transforming growth factor-b (TGF-b)
is a multi-functional peptide with opposite roles in prostate tumorigenesis as an inhibitor in
normal growth and early stage disease and a promoter in advanced prostate cancer. Dysregu-
lated TGF-b signaling leads to a cascade of events contributing to oncogenesis, including up-
regulated proliferation, decreased apoptosis, epithelial-to-mesenchymal transition (EMT)
and evasion of immune surveillance. TGF-b signaling pathway presents an appropriate venue
for establishing a therapeutic targeting platform in CRPC. Exploitation of TGF-b effectors
and their cross talk with the androgen axis pathway will provide new insights into mechanisms
of resistance of the current antiandrogen therapeutic strategies and lead to generation of new
effective treatment modalities for CRPC. Points of functional convergence of TGF-b with key
oncogenic pathways, including mitogen-activated protein kinase (MAPK) and androgen recep-
tor (AR), are discussed as navigated within the EMT landscape in the tumor microenvironment.
In this context the emerging anti-TGF-b pharmacotherapies for prostate cancer treatment are
considered. Targeting the functional cross-talk between the TGF-b signaling effectors with the
androgen axis supports the development of novel therapeutic strategies for treating CRPC with
high specificity and efficacy in a personalized-medicine approach.
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1.1. Challenge of castration-resistant-prostate
cancer
Prostate cancer is the second most frequently diagnosed
cancer in men, following lung cancer, with a total of
238,590 new cases and 29,720 deaths in 2013 in the United
States. Prostate cancer is responsible for 28% of the cancer
diagnose and 10% of cancer deaths in men [1]. In addition,
prostate cancer is most frequently diagnosed in aging male.
Histological evidence of prostate cancer were found in
almost 30% of men over the age of 50 years [2]. The
increasing aged population in the US will make prostate
cancer a greater health burden. By 2030, population of 65-
year-plus age group is predicted to reach 72 million and
concomitant increase in prostate cancer incidence will be
inevitable [3]. Improvements in diagnostic, surgical and
radiation techniques, and using of androgen-deprivation
therapy (ADT) slow the disease progression and decrease
the death rate of prostate cancer patients [4]. Although the
consequence of ADT remains controversial, medical or
surgical castration remains the standard of care for patients
with advanced disease [5]. Following such ADT however
patients eventually develop castration-resistant prostate
cancer (CRPC) after 1e3 years [6]. Clinical progression of
CRPC is manifested as biochemical progression (elevated
prostate specific antigen [PSA]), radiographic progression
(metastatic CRPC), or symptomatic progression [4]. Until
2010, the microtubule-targeting agent, docetaxel was the
only first chemotherapy with survival benefit (2e3 months)
in CRPC. More recently another taxane family member,
cabazitaxel, a second-line chemotherapeutic, in combina-
tion with bevacizumab, thalidomide, and prednisone, was
reported to increase patient survival, but only at a modest
degree [7]. The second-line antiandrogens (agents target-
ing the androgen signaling axis), abiraterone and enzalu-
tamide, led to increased survival by 5 months. In addition,
the immunotherapeutic, sipuleucel-T, increased survival of
CRPC patients by 4 months. The radiopharmaceutical
radium-223 increased patient survival by 3 months [7].
1.2. Signaling of transforming growth factor-b
(TGF-b)
Transforming growth factor-b (TGF-b) is a multifunctional
peptide belonging to a superfamily cytokines [8]. TGF-b
regulates cell proliferation, apoptosis, cell differentiation,
and cell migration in multiple types of cells [9]. TGF-b
constitutes three isoforms that share high homology, but
unique heterologous motifs exist in each isoform. TGF-b-
knockout is lethal to mice with survival up to 3e5 weeks
[10e12]. Pro-TGF-bs, 75-kDa homodimers, are initially
synthesized and then cleaved in Golgi to produce mature
25-kDa TGF-b homodimers. The TGF-b homodimers bind
latency-associated proteins, generating small latent com-
plex. A single latent TGF-b binding protein interacts with
the TGF-b homodimer via a disulfide bond, generating a
large latent complex in the endoplasmic reticulum. The
large latent complexes are exported to the extracellular
matrix to interact with fibronectin fibrils and heparinsulfate proteoglycans on the cell membrane and are stored
in fibrillin-rich microfibrils in extracellular matrix. Latent
TGF-b is activated and released from the latent complex by
proteases, reactive oxygen species, integrins and throm-
bospondin 1 to initiate signaling [13].
TGF-b signaling is mediated through SMAD and non-SMAD
pathways. In the SMAD dependent pathway, TGF-b binds to
a type II receptor, TGF-bRII, followed by recruitment and
phosphorylation of a type I receptor, TGF-bRI, at the serine
and threonine residues. TGF-bRI serine/threonine kinase is
activated by phosphorylation and the activated type I re-
ceptor recruits and phosphorylates downstream receptor
regulated SMAD (R-SMAD), including R-SMAD2 and R-SMAD3.
Subsequently, R-SMAD2 and R-SMAD3 form complexes with
the cytosolic SMAD4, which are translocated to the nucleus
to regulate target gene expression [9]. TGF-b inhibits pro-
liferation and induces apoptosis in normal prostate
epithelial cells and early stages of prostate cancer cells.
Activated SMAD cascade leads to G1 arrest accompanied by
up-regulation of cyclin-dependent kinase inhibitors [14]
and down-regulation of c-Myc oncogene [15]. In addition,
TGF-b1 signaling promotes apoptosis by inducing death
associated protein kinase in a SMAD-dependent manner in
the liver [16]. SMAD4 induces transcriptional activation of
the translation-inhibiting protein 4E-BP1 (eukaryotic
translation initiation factor 4E-binding protein 1) and cat-
alytic inactivation of the translation initiation factor
eEF1A1 (eukaryotic elongation factor 1A1), establishing the
translational regulating effect [17,18]. In contrast to the
agonistic SMADs, inhibitory SMADs, SMAD6/7, negatively
regulate R-SMAD activity and nuclear translocation [6].
Upon TGF-b activation, SMAD7 is recruited to TGF-bRI to
block SMAD2/3 phosphorylation. In addition, SMAD7 induces
proteasomal degradation of TGF-bRI, TGF-bRII, and other
SMAD transcription factors to inhibit TGF-b signaling [19]. In
addition to the SMAD dependent pathway, non-SMAD path-
ways, including MAPK, c-Src, m-TOR, RhoA, RAS, PI3K/Akt,
protein phosphatase 2A/p70s6K [6,20], as well as the actin
cytoskeleton effector cofilin [21,22] are regulated by
TGF-b.
The clinical significance of targeting TGF-b signaling is
built on a strong body of evidence demonstrating that loss
of TGF-bRII and/or TGF-bRI receptors is associated with
decreased survival rate of colon cancer, breast cancer, and
prostate cancer patients [23e25]. At the cellular level, up-
regulation of TGF-bRII promotes the pro-apoptotic function
of TGF-b1, while receptor inactivation induces malignant
transformation [26,27]. Restoration of TGF-b1 signaling by
overexpressing TGF-bRII suppresses prostate tumorigenic
growth in vivo via a caspase-1-mediated mechanism [26].
More recent evidence indicated an association between
reduced expression of TGF-bRII mRNA with higher Gleason
score and elevated risk of relapse after ADT in prostate
cancer patients, supporting the significance of TGF-b1
pathway in CRPC [28]. TGF-b type III receptor (TGF-bRIII or
betaglycan) has also been defined as critical effector of
TGF-b signaling, involved in prostate cancer progression. In
general, TGF-bRIII facilitates signaling by increasing the
affinity of TGF-b, especially TGF-b2, for its receptor [29].
TGF-bRIII binds GAIP (G alpha interacting protein) at the
cell membrane to enhance TGF-b signaling, as well as minor
effect on migration and invasion [29]. In contrast, soluble
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TGF-b signaling [29]. Meanwhile, interaction of TGF-bRIII
with b-arrestin2 leads to co-internalization of TGF-bRIII
with TGF-bRI/II, which further down-regulates TGF-b
signaling [29]. A significant reduction or complete loss of
TGF-bRIII is frequently associated with prostate cancer
progression [30]. Further TGF-bRIII downregulation is
detected in metastases relative to primary tumors [29].
Function loss of TGF-bRIII leads to increase of cells exhib-
iting stem cell characteristics, and alteration of genes
commonly associated with prostate cancer progression
[30]. Restoration of TGF-bRIII expression in human prostate
cancer cells leads to inhibition of migration and invasion
independent of the ligand TGF-b [31]. In a human prostate
cancer xenograft model, restoring TGF-bRIII function de-
creases tumor growth, suggesting its tumor suppressor role
[32].
In benign epithelial cells, TGF-b inhibits epithelial pro-
liferation and promotes apoptosis via SMAD control over c-
Myc and cyclin-dependent kinase inhibitors [14,15]. In
advanced prostate cancer, the functional distribution of
action between SMAD-dependent and -independentFigure 1 TGF-b signaling pathway in prostate cancer cells. The
(serine threonine kinase), subsequently recruiting TGF-bRI, to form
TGF-bRIII transmembrane receptor. The activated receptoreligand
cytoplasm (receptor activated SMADs) and subsequent formation an
in the nucleus activated Smad4 induces gene transcription for TGF-
and EMT. SMAD6/7 negatively regulates R-SMAD activity and nucle
activity, and ultimately TGF-b1-induced growth inhibition and ap
regulated by TGF-b to promote tumor growth and invasion. In add
regulated angiogenesis and MMP-9-induced cell invasion. Cofilin co
and metastatic properties. P, phosphorylation.signaling is apparently disrupted. Thus TGF-b switches to a
tumor promoter enabling prostate cancer progression to
metastasis, by dysregulation of several oncogenic factors
and bypassing the classic pathway of TGF-b signaling acti-
vation (Fig. 1) [20]. Differential activation of MAP kinases
ERK between benign and malignant cells is reported to
control TGF-b synthesis in a homeostatic feedback manner
[33]. TGF-b-induced ERK activation promotes TGF-b syn-
thesis in prostate cancer cells, while it is repressed by
benign prostate cells. In a mechanistic twist, TGF-b-
induced ERK activation cannot be inhibited in advanced
prostate cancer and thus the negative feedback loop is
interrupted [33]. Constitutive ERK activation independent
of TGF-b contributes to continuous production of TGF-b in
prostate cancer cells [33]. In addition, control of receptors
TGF-bRI and TGF-bRII gene methylation proceeds via ERK
activated DNA methyltransferase (DNMT) function [34].
DNMT expression is up-regulated by TGF-b and this conse-
quentially results in hypermethylation of TGF-bR promoters
and down-regulation of their expression [34]. TGF-b and/or
DNMTs overexpression have been correlated with aggressive
prostate tumor phenotypes and more significantly asligand TGF-b binds to cell transmembrane receptor TGF-bRII
receptoreligand complex. This process can be promoted by the
complex leads to phosphorylation of SMAD2 and SMAD3 in the
d nuclear translocation of SMAD2/3 and SMAD4 complex. Once
b target genes regulating proliferation, apoptosis, angiogenesis
ar translocation. AR inhibits the TGF-b1/SMAD transcriptional
optosis. Non-SMAD pathways, including ERK and PI3K/AKT are
ition, TGF-b promotes tumor growth and metastasis by VEGF-
ordinates responses to TGF-b required for migratory, invasive
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translational modification of TGF-bRI involves its ubiquiti-
nation by an ubiquitin ligase tumor necrosis factor receptor
associated factor (TRAF6) and subsequent cleavage by
ADAM metallopeptidase domain 17 (ADAM17), ultimately
inhibiting TGF-b signaling [35]. Cleavage of TGF-bRI gen-
erates an intracellular domain (ICD) that is translocated to
the nucleus, leading to up-regulation of other oncogenic
factors [35]. Cofilin is an F-actin-severing protein involved
in cytoskeleton reorganization and filopodia formation.
Cofilin binding and severing of F-actin contributes to cell
migration during invasion and metastasis of prostate cancer
[36]. Recent studies from this laboratory established that
constitutively active cofilin (Fig. 1) facilitated filopodia
formation and cell migration induced as mediated by TGF-
b, and coordinated responses to TGF-b required for invasive
cancer migration and metastasis [21].
2. Merging pathways of TGF-b signaling and
androgen axis in prostate cancer
Androgenic hormones, testosterone and its metabolite
dihydrotestosterone (DHT), bind AR in the cytoplasm to
induce nuclear translocation and transcriptional activation
of target genes. Androgens promote prostate epithelial cell
proliferation in the absence of stroma fibroblasts by
engaging different cytokines, although in the presence of
surrounding prostate stroma this effect is biphasic [37].
TGF-b signaling is mediated through SMAD and non-SMAD
pathways towards apoptosis induction and inhibition of
proliferation in early tumor development, while it pro-
motes progression to metastasis in advanced disease [6,20].
TGF-b treatment and physiological levels of DHT in LNCaP
TGF-bRII cells enhances cell cycle arrest and apoptosis
compared to TGF-b treatment alone [38]. Such combined
TGF-b and DHT-induced apoptosis is inhibited by caspase-1
inhibition and Bcl-2 overexpression in prostate cancer cells
[38,39]. AR inhibits TGF b1-induced transcriptional activity
in prostate cancer cells in the presence of an AR co-
activator, AR-associated protein 55 (ARA55). Mechanisti-
cally overexpression of ARA55 inhibits TGF-b-mediated up-
regulation of SMAD transcriptional activity via an interac-
tion between C terminus of ARA55 and the MH2 domain of
AR [40]. Direct interaction of TGF-b1 transcription with
androgen and AR complex has been reported in human
hepatoma cells [41]. In human prostate cancer cell lines,
PC-3 and LNCaP, SMAD4 alone or the SMAD3/4 complex,
interact with the AR transcriptional activation domain,
regulating DHT-induced AR transcriptional activity [37,42].
In the androgen-independent PC-3 cells, forced expression
of AR inhibits the TGF-b1/SMAD transcriptional activity, as
well as TGF-b1-induced growth inhibition and apoptosis
[37]. Mechanistic evidence indicates that AR-induced
transcriptional suppression of SMAD3 is responsible for the
inhibition of tumor suppressor function of TGF-b in prostate
cancer [42,43]. AR suppresses expression of TGF-b1 through
a negative androgen-response region containing multiple
negative androgen-response elements in the TGF-b1 pro-
moter in androgen-independent and androgen-sensitive
human prostate cancer cells [44]. AR knockdown in
carcinoma-associated fibroblasts (CAFs) leads to decreasedexpression of TGF-b2, indicating that AR by regulating
TGF-b promotes prostate cancer epithelial growth and in-
vasion [45]. In addition, AR and miR-21 increase each
other’s expression and promote tumor growth by attenu-
ating TGF-bRII expression and TGF-b-induced SMAD2/3
activation [46]. Investigation of this dynamic interaction
between TGF-b and AR signaling mechanism will potentially
lead to new platforms for therapeutic management of
advanced metastatic prostate cancer.
3. Landscape design by TGF-b:
epithelialemesenchymal transition (EMT)
TGF-b induces epithelialemesenchymal transition (EMT) to
facilitate tumor progression and metastasis [6]. EMT
phenotype is characterized by loss of E-cadherin and
expression of mesenchymal proteins, including N-cadherin,
vimentin, and fibronectin. Transcriptional repression of
E-cadherin and induction of mesenchymal phenotype can
be facilitated by TGF-b in cancer cells [6]. In prostate
cancer, TGF-b1 induces EMT in prostate tumor epithelial
cells and in a mouse model of tumorigenesis with a targeted
deletion of SMAD3, supporting a contributing role for TGF-b
signaling to EMT and prostatic cancer metastasis [47,48].
TGF-b induces EMT in prostate tumor through constitutively
active Akt that inhibits translocation of SMAD3 and p21 to
the nucleus [47]. Inhibition of vimentin, a mesenchymal
type III intermediate filament, is sufficient to partially
reverse EMT in prostate cancer cell lines, pointing to a
therapeutic targeting value for vimentin [49]. In PC-3
prostate cancer cells, blockade of NF-kB signaling leads to
decreased vimentin expression and inhibition of their
invasive capability, indicating functional involvement of
NF-kB in mediating TGF-b-induced EMT [50]. Other tran-
scription factors, such as SNAI2/Slug that control E-cad-
herin expression (epithelial cell marker), are causally
involved in TGF-b1-induced EMT in non-transformed pros-
tate cells, conferring loss of polarity at the invading front
[51]. In benign epithelial cells, EMT transcriptional in-
ducers, Snail and Twist, contribute to the appearance of
CD44Hi/CD24low cancer stem cells phenotype, implicating
EMT as the process driving acquisition of stemlike charac-
teristics in cancer cells [52].
A wealth of evidence has established the ability of TGF-b
to up-regulate matrix metalloproteinase-9 (MMP-9) via
translocation of TGF-bRI-ICD to the nucleus, promoting
tumor invasion [35,53]. Recombinant soluble betaglycan
inhibits DU145 human prostate cancer cell xenograft
growth, tumor blood volume and microvessel density, and
an elevation of apoptosis by inhibiting TGF-b-induced
MMP-9 activity and expression [32]. Anethole, an aromatic
compound with antitumor activities, impairs prostate can-
cer metastasis by decreasing expression of MMP-9 and up-
regulating the cell adherens junction mediator, E-cad-
herin [54]. Such metastasis-blocking effects are reversed by
TGF-b-induced EMT, indicating a crosstalk between EMT
effectors and MMP-9 in prostate tumor progression to
metastasis. Moreover, clinically used first and second gen-
eration anti-androgens, Casodex or MDV3100 (enzaluta-
mide), suppress prostate cancer cell growth yet promote
prostate cancer cell invasion by activating the TGF-b1/
TGF-b in prostate tumorigenesis 15SMAD3/MMP9 pathway [55]. A newly developed anti-AR
compound, ASC-J9, produces anti-invasion effects against
prostate cancer by down-regulating MMP9 expression [55].
Endothelial cell-induced prostate cancer invasion can be
functionally prevented by blocking the IL-6/AR/TGF-b/
MMP-9 signaling pathway [56]. In addition to prostate can-
cer, TGF-b1 up-regulates MMP-9 expression and activity in
human skin, corneal epithelial cells, and brain astrocytes,
indicating potential therapeutic benefits in multiple clinical
settings [56]. Recently identified additional molecular ef-
fectors of TGF-b signaling have been directly implicated in
prostate cancer cell progression and metastasis [57,58].
NEDD9, one of the Crk-associated substrate family proteins,
is shown to mechanistically drive TGF-b-induced EMT in
prostate cancer epithelial cells, ultimately emerging as a
potential marker, as well as a target for metastatic disease
[57]. Clusterin is a pleiotropic molecular chaperone that
has recently emerged as an essential effector of TGF-b-
induced EMT, with a promise for therapeutic targeting po-
tential in prostate cancer progression [58].
4. Dictations by TGF-b in the prostate tumor
microenvironment
The prostate microenvironment plays an important role in
the development and progression of prostate cancer [6].
Diverse cell types including carcinoma-associated stromal
cells (CAFs), endothelial cells, lymphocytes and cancer
epithelial cells comprise the dynamic tumor microenviron-
ment, under the regulatory control of TGF-b to promote
tumor growth and progression [59]. While normal fibro-
blasts are responsible for maintaining tissue homeostasis,
myofibroblasts and CAFs facilitate tumor progression via
their repair-centric system and pro-survival biology, pro-
moting new growth and vascularity. Establishment of
vascular supply and angiogenesis allow for exchange of
nutrient and waste, further facilitating prostate cancer
progression and metastasis [59]. Generation of myofibro-
blasts in the prostate tumor microenvironment is dynami-
cally controlled by TGF-b signaling [60]. Targeted
overexpression of TGF-b1 in the mouse prostate gland leads
to increased frequency of unique fibrotic collagenous
micronodules, associated with clinical prostate cancer
initiation [61]. Silibinin, an extract of the milk thistle seeds,
inhibits prostate cancer cell-mediated differentiation of
naı¨ve fibroblasts into CAFs via inhibition of TGF-b2
expression in PC-3 cells, further supporting a role of TGF-b
in fibroblast differentiation [60]. Another forum via which
TGF-b1 exerts its control over the tumor microenvironment
dynamics, is via its stimulatory effect on vascular endo-
thelial growth factor (VEGF), the critical regulator in
angiogenesis, in human prostate cancer PC-3-M and LNCaP
C4e2B cells [62]. Upregulation of VEGF expression proceeds
via SMAD complex regulated transcription, and the Src/
FAK/Akt signaling pathways [62]. Apigenin, a natural
product belonging to the flavone, decreases VEGF expres-
sion by selectively inhibiting TGF-b1-induced phosphoryla-
tion of SMAD2 and SMAD3, further supporting the functional
involvement of TGF-b in angiogenesis [62]. TGF-b exerts its
regulatory role in angiogenesis, invasion and migration and
EMT via navigating an array of interactions between tumorepithelial cells and myofibroblasts/CAFs maintaining a
reactive tumor microenvironment, crucial to prostate
cancer metastatic spread [21,59,63].
5. TGF-b in control of immune surveillance
TGF-b, also serves as a role of a repressor of the immune
system via its ability to regulate T-cells. Full activation of
T-cells is inhibited by constitutive active receptor TGF-bRI
[64]. TGF-b1 knockout in mice specific and ablation of
TGF-bRII in T-cells lead to autoimmunity [65]. T-cell and
tumor-induced TGF-b inhibit surrounding host immune
cells, resulting in cancer cell evasion of the host immune
surveillance, towards tumor progression [66]. In addition to
suppressing the effector T-cell function, TGF-b induces
regulatory T-cells to repress effector T cells-induced cyto-
toxicity and inflammation [67]. Forkhead family transcrip-
tion factor, Foxp3, regulates development and function of
regulatory T-cells [67]. TGF-b induces transcription factor
Foxp3 to convert CD4þCD25 naive T cells to CD4þCD25þ
regulatory T-cells and maintains Foxp3 expression [68].
Interestingly enough, tumor-reactive TGF-b-insensitive
CD8þ T-cells infiltrate into the tumor parenchyma and
induce tumor cell apoptosis, indicating the ability of TGF-b
to navigate evasion of the immune system by tumor cells
[69].
6. Targeting value of TGF-b mechanisms in
prostate tumor progression
Several transgenic mouse models have been generated and
characterized to interrogate the molecular events that
drive prostate cancer initiation, progression, and metas-
tasis. The Pten knockout, the Nkx3.1 knockout, the trans-
genic adenocarcinoma of the mouse prostate (TRAMP)
mouse model and probasin-large T-antigen transgenic
mouse (LADY) model have been established and effectively
exploited [70]. Work from this laboratory demonstrated
that dominant-negative mutant TGF-bRII receptor accel-
erates prostate tumorigenesis in the TRAMP mouse model
by enhancing EMT and disrupting the growth kinetics within
the tumor microenvironment [27]. In vivo evidence gath-
ered from different investigations provides solid support for
this action: First, conditional knockout of TGF-bRII receptor
in stromal fibroblasts leads to prostatic intraepithelial
neoplasia and adenocarcinoma, and ultimately bone met-
astatic growth [63,71]. Furthermore, in a constitutively
active TGF-b1 transgenic mouse model, inflammation of
nerve ganglia and fibroplasia occurs in an age-dependent
manner in the prostate stroma [59]. Development of
poorly differentiated prostate adenocarcinoma in Ras and
Myc-driven mouse models, is associated with elevated
TGF-b1 [72]. Loss of SMAD4 function (nuclear effector of
TGF-b) leads to invasive and metastatic prostate cancer
with 100% penetrance in the Pten-null mouse prostate,
further supporting the significance of TGF-b signaling in
prostate cancer progression to lethal disease [73].
The complexity of the mechanisms navigating the dual
function of TGF-b as an inhibitor of prostate tumor growth
in early stage cancer, and a promoter of progression to
metastasis in advanced stages, requires exhaustive
16 Z. Cao, N. Kyprianouunderstanding of its signaling interactions with critical cell
survival pathways, primarily the androgen axis [37]. Thus, it
is clear that timing of anti-TGF-b directed therapies is of
paramount significance in effectively targeting the func-
tional contribution of TGF-b to impair progression to
metastasis. Small molecules inhibiting the kinase activity of
TGF-b receptors such as LY2157299, a kinase inhibitor tar-
geting ATP-binding site of TGF-bRI, are in Phase I clinical
trial, with good safety profile in patients with prostate
cancer [74], as well as colon and breast cancer [75].
Another kinase inhibitor, LY573636, is currently investi-
gated in a Phase II clinical trial in patients with advanced
stage melanoma [74].
The therapeutic value of targeting TGF-b in the context
of immunotherapy approach has also been pursued. FC1008,
a neutralizing antibody that bind all isoforms of TGF-b, is
undergoing a Phase I/II clinical trial to treat breast cancer
and pleural mesothelioma [76]. Antisense inhibition of
oncogene expression provides a potential therapeutic
platform for treatment of several malignancies [77]. Spe-
cifically for prostate cancer, an antisense oligonucleotide
targeting TGF-b1, AP11014, decreases TGF-b1 secretion by
prostate cancer cells [74]. AP 12009, an antisense oligonu-
cleotide targeting TGF-b2, is safe and well-tolerated in
patients with high-grade glioma, and a Phase I/II clinical
trial in pancreatic carcinoma and malignant melanoma is
currently under investigation [74]. In breast cancer, soluble
TGF-bRII receptor can sequester TGF-b from the cellular
receptors, to inhibit cell survival, migration, and metasta-
ses [78], and in vivo prostate cancer growth [32]. ASC-J9, a
recently developed anti-AR compound, prevents prostate
cancer cell growth as well as metastasis by down-regulating
MMP9 activity and expression [55].
7. Conclusion
TGF-b signaling pathway has been extensively studied as a
potential therapeutic target to treat prostate cancer [6].
TGF-b receptor inhibitors have been evaluated in pre-
clinical in vivo models, as well as in the clinical setting of
prostate cancer patients [6]. Considering the dual function
of TGF-b in prostate tumorigenesis, as an inhibitor of
prostate tumor growth in early stage cancer and a promoter
of progression to metastasis in advanced stages, as well as
its role in repression of the immune system, therapeutics
only inhibiting the tumor-promoting action of TGF-b could
be challenging in eliciting a therapeutic effect. Conse-
quently, treatment strategies based on the use of TGF-b
signaling inhibitors must clinically be considered with
caution and in the context of personalized therapy
approach for targeting individual patients with CRPC based
on their molecular signature profile. Exploitation platforms
must include points of the multi-cytokine convergence of
TGF-b signaling, the androgen-AR axis and the EMT land-
scape in the prostate tumor microenvironment, presenting
therapeutic optimizing options for personal combination
therapeutic strategies.
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